Atara Seeks FDA Type A Meeting, Submits Efficacy Data for Tab-cel Resubmission
Pierre Fabre Pharmaceuticals and Atara Biotherapeutics have requested an FDA Type A meeting to address the January 9, 2026 Complete Response Letter for tabelecleucel. Their briefing book includes evidence that the ALLELE study is adequate, updated long-term efficacy data, supportive program results and European post-marketing findings.
1. Regulatory Meeting Request
Pierre Fabre Pharmaceuticals, in partnership with Atara Biotherapeutics, has formally requested a Type A meeting with the FDA to discuss the Complete Response Letter issued on January 9, 2026, for the tabelecleucel Biologics License Application.
2. Data Package Highlights
The submitted briefing book contends that the ALLELE study was adequate, well-controlled and sufficient to support approval, and presents updated longer-term efficacy results, additional supportive data from the tab-cel development program, and European post-marketing safety and efficacy observations.
3. Next Steps and Timeline
Atara and Pierre Fabre aim to engage in constructive FDA discussions to clarify requirements and potentially pursue a timely BLA resubmission for accelerated approval of tabelecleucel in EBV+ post-transplant lymphoproliferative disease.